BioSyent (CVE:RX) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?

BioSyent Inc. (CVE:RX) passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$11.25 and traded as high as C$12.12. BioSyent shares last traded at C$12.12, with a volume of 6,657 shares trading hands.

Analyst Ratings Changes

Separately, Bloom Burton upgraded shares of BioSyent from a “moderate buy” rating to a “strong-buy” rating in a research report on Friday, November 21st. One research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Strong Buy”.

BioSyent Price Performance

The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90. The stock has a market cap of C$136.72 million, a PE ratio of 16.23 and a beta of 0.53. The business has a 50-day moving average price of C$11.26 and a 200 day moving average price of C$11.54.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.